Clinical Trials Browser

Phase 3 × Interventional × zanubrutinib × Clear all

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT07277231 2026-03-18

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Phase 3 Recruiting

500 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03336333 2026-03-09

SEQUOIA

Phase 3 Active not recruiting

590 enrolled 12 charts 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05976763 2026-03-04

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Phase 3 Recruiting

421 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT06073821 2026-03-04

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

Phase 3 Active not recruiting

652 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06742996 2026-02-20

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

Phase 3 Recruiting

300 enrolled

Lymphoid

Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT04170283 2025-10-21

Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

Phase 3 Active not recruiting

955 enrolled

Lymphoid

B-cell Malignancies

NCT04002297 2025-09-26

MANGROVE

Phase 3 Active not recruiting

510 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT04662255 2025-05-28

BRUIN-MCL-321

Phase 3 Active not recruiting

500 enrolled

Lymphoid

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT03734016 2025-03-30

ALPINE

Phase 3 Completed

652 enrolled 27 charts 1 FDA

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03053440 2024-10-26

ASPEN

Phase 3 Completed

201 enrolled 19 charts 1 FDA

Lymphoid

Waldenstrom Macroglobulinemia

NCT06522555 2024-08-05

The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma

Phase 3 Recruiting

100 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

Clinical Trials

MAHOGANY

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

SEQUOIA

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

MANGROVE

BRUIN-MCL-321

ALPINE

ASPEN

The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma